Crucell N.V. Announces PER.C6(R) and AdVac(R) Technology License Agreement with Wyeth Pharmaceuticals
Leiden, The Netherlands, July 30 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE - News).